SEC Form 4 · accession 0001562180-19-000094
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay Strum
Officer — Chief Scientific Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 2, 2019 · 5:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2019 | M | 39,485 | $0.30 | A | 88,904 | D | |
| Common Stock | Jan 2, 2019 | M | 40,333 | $0.39 | A | 129,237 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.56 | Jan 2, 2019 | A | 15,000 | A | — | Jan 2, 2029 | Common Stock | 15,000 | 15,000 | D |
| Stock Option (Right to Buy)F2 | $0.39 | Jan 2, 2019 | M | 13,333 | D | — | Jan 21, 2024 | Common Stock | 13,333 | 0 | D |
| Stock Option (Right to Buy)F2 | $0.39 | Jan 2, 2019 | M | 27,000 | D | — | Jul 11, 2024 | Common Stock | 27,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $0.30 | Jan 2, 2019 | M | 15,816 | D | — | Nov 9, 2022 | Common Stock | 15,816 | 0 | D |
| Stock Option (Right to Buy)F2 | $0.30 | Jan 2, 2019 | M | 10,336 | D | — | Jan 9, 2023 | Common Stock | 10,336 | 0 | D |
| Stock Option (Right to Buy)F2 | $0.30 | Jan 2, 2019 | M | 13,333 | D | — | Apr 16, 2023 | Common Stock | 13,333 | 0 | D |
Explanation of responses
- F1The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- F2All shares underlying this option have vested.